Financial success in biotechnology: company age versus company science

Our results are that older companies have significantly higher stock market valuations, and that those companies had fewer PhD's as their Chief Executive Officers (CEOs). These findings suggest that the stock market often looks favourably upon older established biotechnology companies that are run by professional managers rather than pioneering scientists.